From the Editor-in-Chief's Desk

Abstract

Journal of Child and Adolescent PsychopharmacologyVol. 33, No. 1 EditorialFree AccessFrom the Editor-in-Chief's DeskHarold S. KoplewiczHarold S. KoplewiczChild Mind Institute, New York, New York, USA.Search for more papers by this authorPublished Online:14 Feb 2023https://doi.org/10.1089/cap.2022.29234.editorialAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail To Our Readers:I hope the beginning of 2023 has brought joy and a renewed sense of purpose to everyone! The first thing I would like to share is an exciting update from the Child Mind Institute. I am pleased to announce our latest initiative in collaboration with the State of California, the Youth Mental Health Academy.In its inaugural year, the academy will identify and support 2500 talented and diverse high school students with an interest in child and adolescent mental health, and engage them in summer internships with stipends, peer mentorship, and professional development. Recruitment for the academy will be from groups under-represented in our field today, including young people of color and LGBT youth. While moving our field toward being more representative and understanding of the populations in need of our services, we will inspire and cultivate the mental health leaders of tomorrow.I would like to highlight two articles in this issue of the journal. In “Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day,” Faraone et al. report evidence of this treatment's usefulness in children ages 6–12 years. Their study applies a post-hoc analysis to a randomized double-blind placebo-controlled assessment to evaluate outcomes at different timepoints from morning through evening.The authors emphasize the need for medication that works throughout the day, pointing out the pervasive effects of attention-deficit/hyperactivity disorder (ADHD) in children's lives both in the classroom and outside of school. The analysis yielded a large and consistent effect size across the day. But they point out two limitations to their promising findings: the nature of the analysis is posthoc and the sample size is relatively small.The second article I would like to highlight discusses a study that sets out to determine any effects on the cognitive, emotional, and physical development of children ages 6–16 years after treatment with sertraline for up to 3 years. In their article titled, “Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES),” Kolitsopoulos et al. explain that their study compared 695 participants who were exposed to sertraline with or without psychotherapy with 245 participants who were exposed to psychotherapy alone.Of the original participants, 432 completed the full 3-year study. A small but statistically significant increase in weight was observed in the participants exposed to sertraline, but otherwise, results for the group exposed to sertraline displayed normal development and showed no significant changes over time.I hope you find the articles in this issue helpful and informative. Welcome to the new year!Harold S. Koplewicz, MDEditor-in-ChiefFiguresReferencesRelatedDetails Volume 33Issue 1Feb 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Harold S. Koplewicz.From the Editor-in-Chief's Desk.Journal of Child and Adolescent Psychopharmacology.Feb 2023.1-1.http://doi.org/10.1089/cap.2022.29234.editorialPublished in Volume: 33 Issue 1: February 14, 2023PDF download